piracetam
Small moleculeexperimental
Piracetam is a drug that has efficacy in cognitive disorders, vertigo, cortical myoclonus, dyslexia, and sickle cell anemia; sources differ on its usefulness for dementia. Piracetam is sold as a medication in many European countries. Piracetam in the United States is not approved for general use. — Wikipedia
Clinical trial activity
9 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
3
Phase 4
2
Earliest trial started Oct 1, 1996 (NCT00000198)
Timeline
Indications
Approved for
Studied for
- Alzheimer Disease · Phase 4
- Anxiety Disorders · Phase 3
- Cocaine-Related Disorders · Phase 1
- Dementia · Phase 3
- Dementia, Vascular · Phase 4
- Depression · Phase 3
- Postpoliomyelitis Syndrome · Phase 3
- Psychophysiologic Disorders · Phase 3
- Schizophrenia · Phase 3
- Stroke · Phase 4
- Tardive Dyskinesia · Phase 3
- Vertigo · Phase 4
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
NC(=O)CN1CCCC1=O- Mol. weight
- 142.16 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPiracetam ↗
- ChEMBLCHEMBL36715 ↗
Also known as
- 2-pyrrolidinoneacetamide
- cl-871
- cl-871
- gabacet
- gabacet
- neuracetam
- nootrop
- nootrop
- nootrop 1200
- nootrop 400
- nootrop 800
- nootropil
- nootropil
- nootropil
- piracetam
- piracetam
- piracetam
- piracetam
- piracetam
- piracetam
- piracetam
- pirazetam
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03835325 | N/A | Jan 23, 2019 | Eurofarma Laboratorios S.A. |
| NCT02374567 | Phase 3 | Jan 1, 2015 | Gottfried Wilhelm Leibniz Universität Hannover |
| NCT01890538 | Phase 4 | Jun 1, 2013 | Kocaeli University |
| NCT01549847 | Phase 3 | Mar 7, 2012 | Biolab Sanus Farmaceutica, University of Sao Paulo |
| NCT00190008 | Phase 3 | Aug 1, 2003 | Ben Gurion University, Stanley Medical Research Institute |
| NCT00567060 | N/A | May 1, 2000 | Hoosier Cancer Research Network |
| NCT00000199 | Phase 1 | Sep 20, 1999 | National Institute on Drug Abuse (NIDA), University of Pennsylvania |
| NCT01883011 | Phase 4 | Aug 1, 1998 | Hoosier Cancer Research Network |
| NCT00000198 | Phase 1 | Oct 1, 1996 | National Institute on Drug Abuse (NIDA), University of Pennsylvania |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hoosier Cancer Research Network | Academic/Hospital | 2 | 2 | 2 | 1998 |
| National Institute on Drug Abuse (NIDA) | Government | 2 | 0 | 1 | 1996 |
| University of Pennsylvania | Academic/Hospital | 2 | 2 | 1 | 1996 |
| Ben Gurion University | Academic/Hospital | 1 | 1 | 1 | 2003 |
| Biolab Sanus Farmaceutica | For profit | 1 | 1 | 1 | 2012 |
| Eurofarma Laboratorios S.A. | For profit | 1 | 1 | 1 | 2019 |
| Gottfried Wilhelm Leibniz Universität Hannover | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Kocaeli University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Stanley Medical Research Institute | Academic/Hospital | 1 | 0 | 1 | 2003 |
| University of Sao Paulo | Academic/Hospital | 1 | 0 | 1 | 2012 |
10 organizations
Page 1 / 1